Zai Lab Seen 42% Undervalued at $19.22 as Fair Value Model Points to $33.30
Updated
Updated · Simply Wall St · Jul 26
Zai Lab Seen 42% Undervalued at $19.22 as Fair Value Model Points to $33.30
1 articles · Updated · Simply Wall St · Jul 26
Summary
$19.22 shares imply about 42% upside to a modeled fair value of $33.30, putting Zai Lab back in focus after a sharp pullback.
Recent performance has been weak despite that valuation case: the stock fell 2.34% in a day, 4.85% over seven days and 48.29% over the past year.
The bullish thesis rests on 12-18 months of product launches and label expansions — including VYVGART, bemarituzumab, KarXT, TIVDAK and Tumor Treating Fields — plus a broader oncology and immunology pipeline.
That upside still depends on rapid revenue growth, margin improvement and a premium earnings multiple, while competition in China and heavy R&D and SG&A spending could delay profitability.